Oncolytics (ONCY) Receives FDA Orphan Drug Designation for REOLYSIN as Primary Peritoneal Cancers Treatment
Tweet Send to a Friend
Oncolytics Biotech (NASDAQ: ONCY) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
